ALS2 Antibody

What is ALS2 and why is it important in research?

ALS2 (amyotrophic lateral sclerosis 2 juvenile) is a protein encoded by the ALS2 gene (Gene ID: 57679) with a calculated molecular weight of approximately 184 kDa and observed molecular weight of 185 kDa . This protein is significant in research due to its implications in juvenile-onset amyotrophic lateral sclerosis and other neurodegenerative conditions. Pathological variants of ALS2 demonstrate altered oligomerization states that may affect protein function and localization, making it an important target for studies investigating neurodegenerative disease mechanisms . The development of specific antibodies against ALS2 enables researchers to study its expression, localization, and functional characteristics in both normal and pathological states.

What are the main types of ALS2 antibodies available for research?

Researchers can utilize several types of ALS2 antibodies based on their experimental needs. These include polyclonal antibodies that recognize multiple epitopes across the ALS2 protein and monoclonal antibodies that target specific epitopes. According to available data, polyclonal antibodies targeting various regions of ALS2 are common, including those that recognize N-terminal (AA 1-280), central domain (AA 221-320), and C-terminal regions (AA 1248-1277) . Both unconjugated antibodies and those with conjugates can be found, though most ALS2 antibodies identified in the search results are unconjugated . The host animals for these antibodies primarily include rabbit and mouse, with rabbit polyclonal antibodies being particularly prevalent for ALS2 research .

What is the difference between ALS2 in humans and Als2 in Candida species?

It's crucial for researchers to distinguish between human ALS2 and fungal Als2, as they represent entirely different proteins despite the similar nomenclature. Human ALS2 refers to the amyotrophic lateral sclerosis 2 juvenile protein involved in neurodegenerative conditions . In contrast, fungal Als2 refers to agglutinin-like sequence proteins found in Candida species, particularly Candida albicans, which function as cell-surface glycoproteins that mediate adhesive and aggregative interactions with host cells, other microbes, and abiotic surfaces . Monoclonal antibodies have been developed specifically for Candida albicans Als2 to study its localization and function in fungal biology and pathogenesis . When designing experiments or interpreting literature, researchers must carefully consider this distinction to avoid confusion between these unrelated proteins.

How should I determine the optimal antibody dilution for my ALS2 western blot experiment?

Determining the optimal antibody dilution requires systematic titration based on the specific antibody and experimental conditions. For ALS2 antibodies used in western blot applications, the recommended dilution range is typically 1:500-1:2000 . The optimal dilution should be established through an initial titration experiment where several dilutions within this range are tested using identical protein samples. Begin with a standard dilution (e.g., 1:1000) and test dilutions above and below (e.g., 1:500, 1:1000, 1:2000). Evaluate signal-to-noise ratio, background levels, and specific band intensity at the expected molecular weight of 185 kDa . It's recommended to include positive controls such as mouse or rat cerebellum tissue or HEK-293 cells, which have been validated to express detectable levels of ALS2 . Remember that the optimal dilution may vary based on protein expression levels in your specific samples, detection method, and the particular lot of antibody being used.

Which tissues or cell lines serve as appropriate positive controls for ALS2 antibody validation?

Based on the search results, validated positive controls for ALS2 antibody testing include:

These tissues and cell lines have demonstrated detectable levels of ALS2 protein and can serve as reliable positive controls for antibody validation experiments . When establishing a new experimental system, it's advisable to include at least one of these validated positive controls alongside your samples of interest. Additionally, using samples from ALS2 knockout models or cells treated with ALS2-specific siRNA as negative controls can provide further confirmation of antibody specificity. The cerebellum tissue samples are particularly valuable for neurological research applications, while HEK-293 cells offer a readily available human cell line option suitable for both western blot and immunoprecipitation techniques .

What are the recommended sample preparation methods for detecting ALS2 in different applications?

Sample preparation methods should be tailored to both the application and the nature of ALS2. For western blot applications, tissues should be homogenized in RIPA buffer supplemented with protease inhibitors, while cultured cells can be directly lysed in the same buffer. Given ALS2's relatively high molecular weight (185 kDa), using low percentage (6-8%) SDS-PAGE gels is recommended for optimal resolution . For immunoprecipitation applications, milder lysis conditions using NP-40 or Triton X-100 based buffers may better preserve protein-protein interactions. The search results indicate that for IP applications, 0.5-4.0 μg of antibody should be used for 1.0-3.0 mg of total protein lysate . For immunohistochemistry applications, paraformaldehyde fixation followed by antigen retrieval is generally appropriate. When working with Als2 from Candida species, special consideration should be given to the protein's glycosylation status, as this can affect antibody recognition. Research has shown that antibodies raised against N-glycosylated Als2 may perform better than those raised against Endoglycosidase H-treated immunogens .

How can I differentiate between specific and non-specific binding when using ALS2 antibodies?

Differentiating between specific and non-specific binding requires a multi-faceted approach incorporating several controls and analytical techniques. First, verify that the observed band appears at the expected molecular weight of 185 kDa for human ALS2 . Second, include positive controls such as mouse or rat cerebellum tissue or HEK-293 cells, which have been validated for ALS2 expression . Third, incorporate negative controls such as ALS2 knockout tissue/cells or samples treated with ALS2-specific siRNA. Fourth, perform peptide competition assays, where pre-incubation of the antibody with the immunizing peptide should abolish specific signals. Fifth, compare results across multiple antibodies targeting different epitopes of ALS2 - concordant results increase confidence in specificity. Finally, consider orthogonal validation through techniques such as mass spectrometry to confirm protein identity. When analyzing western blot data, be aware that ALS2 pathogenic variants may show altered oligomerization states, potentially resulting in molecular weight shifts . These shifts could appear as bands at approximately 700 kDa and 1000 kDa under native conditions, reflecting oligomeric forms rather than non-specific binding .

How should I interpret differences in ALS2 oligomerization patterns in my experimental results?

Differences in ALS2 oligomerization patterns can provide valuable insights into potential pathogenic mechanisms. Research has demonstrated that wild-type ALS2 typically exhibits a specific oligomerization profile, while pathogenic variants show distinctly altered patterns . When analyzing your results, compare the elution profiles of your samples with known patterns: wild-type ALS2 typically shows peak elution at approximately 464 kDa, while pathogenic variants like ALS2 G49R, S100I, C157Y, G540E, and A861_T904del show shifts toward higher molecular weight fractions with peaks at approximately 700 kDa and 1000 kDa . The variant ALS2 R1611W shows an intermediate pattern with broader elution ranging from 400-700 kDa and a minor peak at 1000 kDa . These altered oligomerization states correlate with impaired endosomal localization, suggesting functional consequences of the structural changes. When interpreting your results, consider whether experimental conditions might affect oligomerization independently of pathogenic mutations, such as protein concentration, buffer composition, or post-translational modifications. Quantitative analysis comparing the relative amounts of different oligomeric states can provide additional mechanistic insights into how mutations affect ALS2 function.

What approaches can help resolve contradictory results when studying ALS2 localization?

Contradictory results in ALS2 localization studies can arise from multiple factors including antibody specificity, fixation methods, cell types, and expression levels. To resolve such contradictions, implement a systematic troubleshooting approach. First, verify antibody specificity through appropriate controls and consider using multiple antibodies targeting different epitopes of ALS2. Second, compare results across multiple cell types, as ALS2 localization may be cell-type dependent. Third, evaluate both endogenous and overexpressed ALS2, as overexpression can sometimes lead to artificial localization patterns. Fourth, employ multiple complementary techniques such as immunofluorescence, subcellular fractionation, and proximity labeling to corroborate findings. Fifth, consider the impact of ALS2 oligomerization state on localization, as research has shown that pathogenic variants with altered oligomerization exhibit impaired endosomal localization . Finally, if studying pathogenic variants, directly compare their localization to wild-type ALS2 within the same experimental system to minimize technical variables. When investigating fungal Als2 localization, remember that expression levels of some related proteins (like Als9) may be insufficient for detection in wild-type cells, necessitating overexpression strategies for meaningful analysis .

How can I effectively study the interaction between ALS2 and its binding partners using antibody-based techniques?

Studying ALS2 protein interactions requires strategic application of antibody-based techniques with careful consideration of experimental conditions. For co-immunoprecipitation (co-IP) experiments, use antibodies validated specifically for IP applications, such as those demonstrated to successfully immunoprecipitate ALS2 from HEK-293 cells . When designing co-IP protocols, employ mild lysis conditions (NP-40 or Triton X-100 based buffers) to preserve protein-protein interactions. The recommended antibody amount for ALS2 immunoprecipitation is 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate . For more dynamic analysis of protein interactions, surface plasmon resonance (SPR) can be utilized, similar to methodology described for studying Als protein interactions, where proteins of known concentration are injected over antibody-coated surfaces to determine binding kinetics and affinity . When studying ALS2 variants with altered oligomerization, be aware that these structural changes may directly impact protein-protein interactions. Size exclusion chromatography combined with western blotting can help correlate oligomerization state with interaction capabilities . For challenging or transient interactions, consider crosslinking strategies prior to immunoprecipitation or proximity-based labeling approaches such as BioID or APEX to identify the ALS2 interactome in living cells.

What are the considerations for studying pathogenic ALS2 variants compared to wild-type ALS2?

Studying pathogenic ALS2 variants requires careful experimental design to accurately characterize their molecular differences from wild-type ALS2. First, consider oligomerization patterns, as pathogenic variants (G49R, S100I, C157Y, G540E, A861_T904del) demonstrate distinctly altered oligomerization with shifts toward higher molecular weight fractions (∼700 and ∼1000 kDa) compared to wild-type ALS2 . Second, evaluate subcellular localization, as altered oligomerization in pathogenic variants correlates with impaired endosomal localization . Third, when designing constructs for expression studies, ensure that mutations are introduced precisely without affecting other functional domains. Fourth, include the R1611W variant as an interesting intermediate case that shows a different oligomerization pattern (broadly eluted from ∼400 to ∼700 kDa with a minor peak at ∼1000 kDa) . Fifth, consider using patient-derived cells when available to study variants in their native genomic context. Sixth, employ multiple cell types for validation, as the effect of pathogenic variants might be cell-type dependent. Finally, assess multiple functional readouts including GEF activity, endosomal trafficking, and interaction with binding partners to comprehensively characterize the impact of pathogenic mutations on ALS2 function.

How can I apply ALS2 antibodies to investigate its role in neurodegenerative disease models?

Investigating ALS2's role in neurodegenerative disease models requires strategic application of antibodies across multiple experimental platforms. For in vitro models, immunocytochemistry using ALS2 antibodies can track protein localization in primary neurons or neural cell lines, while western blotting can monitor expression levels under various stress conditions relevant to neurodegeneration. When working with animal models, immunohistochemistry can map ALS2 distribution across brain regions, with particular attention to the cerebellum where ALS2 expression has been validated . For more sophisticated in vivo approaches, consider using intrabodies (intracellularly expressed antibodies) targeting specific domains of ALS2 to interfere with its function in a domain-specific manner. When studying animal models of ALS or other neurodegenerative conditions, longitudinal analysis of ALS2 expression, localization, and oligomerization state can provide insights into disease progression. Flow cytometry with ALS2 antibodies can be used to isolate specific neural cell populations for further analysis. Additionally, emerging techniques like spatial transcriptomics combined with immunofluorescence can correlate ALS2 protein levels with transcriptional changes in disease-relevant brain regions. When designing such experiments, include age-matched controls and consider both acute and chronic disease models to distinguish between immediate responses and adaptive changes.

How can I troubleshoot weak or absent signals when using ALS2 antibodies in western blots?

When encountering weak or absent signals in ALS2 western blots, implement a systematic troubleshooting approach addressing multiple potential factors. First, verify sample integrity by confirming protein concentration and assessing general protein quality through Ponceau S staining of the membrane. Second, optimize protein loading, considering that 184-185 kDa proteins like ALS2 may require higher amounts (50-100 μg) of total protein for clear detection. Third, adjust antibody concentration by testing higher concentrations within the recommended range (1:500-1:2000) or even exceeding it (1:250) if signals remain weak. Fourth, extend primary antibody incubation time to overnight at 4°C to enhance binding. Fifth, optimize transfer conditions for high molecular weight proteins by using lower methanol concentrations in transfer buffer or employing specialized transfer systems for large proteins. Sixth, consider enhancing detection sensitivity by using high-sensitivity ECL substrates or switching to fluorescent secondary antibodies with digital imaging. Seventh, verify ALS2 expression in your samples, as expression levels may vary significantly across tissues and cell types; include validated positive controls such as mouse/rat cerebellum tissue or HEK-293 cells . Finally, if all else fails, try alternative antibodies targeting different epitopes of ALS2, as epitope accessibility can vary depending on protein conformation or post-translational modifications.

What are the key methodological differences when using ALS2 antibodies for studying the human protein versus fungal Als2?

The methodological approaches for studying human ALS2 versus fungal Als2 differ significantly despite their similar nomenclature. For human ALS2, antibodies typically recognize epitopes within specific domains of this 184 kDa protein , while fungal Als2 antibodies target a cell surface glycoprotein in Candida species . When studying human ALS2, western blotting is commonly performed under reducing conditions with samples from neural tissues or cell lines such as HEK-293 . In contrast, fungal Als2 studies often employ immunofluorescence to visualize the protein on the cell surface of yeasts and hyphae . A critical consideration for fungal Als2 is glycosylation status – research has shown that antibodies raised against N-glycosylated immunogens performed better than those raised against Endoglycosidase H-treated proteins . For human ALS2, oligomerization analysis is particularly important, especially when studying pathogenic variants , while for fungal Als2, assessing cross-reactivity with other Candida species (like C. dubliniensis and C. tropicalis) may be relevant . When designing control experiments, human ALS2 studies commonly use brain tissues , whereas fungal Als2 research might require generation of overexpression strains or gene deletion mutants . Remember that fungal Als2 has been demonstrated to be expressed both in vitro and in vivo during infection models , making it relevant to study under diverse environmental conditions.

How can new antibody technologies be applied to advance ALS2 research?

Emerging antibody technologies offer exciting opportunities to advance ALS2 research beyond traditional applications. Single-domain antibodies (nanobodies) against ALS2 could provide superior access to cryptic epitopes and enable super-resolution imaging of ALS2 at subcellular structures. Recombinant antibody fragments with site-specific conjugation allow precise control over labeling stoichiometry for quantitative imaging or proximity-based applications. For studying ALS2 in live cells, genetically encoded intrabodies can track ALS2 dynamics in real-time without fixation artifacts. Consider developing proximity-labeling antibody conjugates (antibody-APEX or antibody-BioID fusions) to map the ALS2 protein neighborhood in specific cellular compartments. Antibody-drug conjugates could be employed in cellular models to achieve targeted degradation of ALS2 or its interaction partners to study functional consequences. For higher throughput analyses, antibody microarrays incorporating ALS2 and related proteins could reveal patterns of expression or post-translational modifications across multiple samples simultaneously. Bi-specific antibodies targeting ALS2 and potential interaction partners could be used to probe protein-protein interactions in situ. Finally, phage display technologies could be employed to develop conformation-specific antibodies that selectively recognize pathogenic oligomeric states of ALS2 identified in prior research , potentially enabling earlier detection of disease-associated structural changes.

What are the considerations for developing phospho-specific ALS2 antibodies for signaling research?

Developing phospho-specific ALS2 antibodies requires careful attention to several key considerations. First, conduct bioinformatic analysis to identify physiologically relevant phosphorylation sites in ALS2 using databases like PhosphoSitePlus, prioritizing evolutionarily conserved sites and those with reported mass spectrometry evidence. Second, design immunogens containing the phosphorylated peptide with sufficient flanking sequence (typically 10-15 amino acids) to ensure appropriate context for antibody recognition. Third, implement rigorous validation strategies including side-by-side testing with phosphatase-treated samples and comparison of antibody reactivity against wild-type ALS2 versus phospho-deficient mutants (serine/threonine to alanine or tyrosine to phenylalanine). Fourth, characterize antibody cross-reactivity against related phosphorylation motifs, particularly important given ALS2's multiple domains. Fifth, optimize immunization protocols to favor phospho-specific antibody production, potentially using strategies to suppress responses to the non-phosphorylated epitope. Sixth, develop paired antibodies that specifically recognize either the phosphorylated or non-phosphorylated form of the same epitope to enable accurate determination of phosphorylation stoichiometry. Finally, validate the phospho-antibodies under physiologically relevant conditions by demonstrating dynamic changes in ALS2 phosphorylation in response to appropriate cellular stimuli or in disease models where ALS2 function may be dysregulated.

How might multiplex imaging with ALS2 antibodies advance our understanding of its role in neurodegeneration?

Multiplex imaging approaches using ALS2 antibodies can significantly advance our understanding of its role in neurodegeneration by revealing complex spatial relationships and molecular interactions. Combining ALS2 antibodies with markers for different cellular compartments (endosomes, lysosomes, autophagosomes) can map its dynamic localization during disease progression, building on observations that pathogenic variants show impaired endosomal localization . Multiplexed immunofluorescence using tyramide signal amplification or DNA-barcoded antibodies allows simultaneous visualization of ALS2 alongside multiple interaction partners and signaling molecules within the same tissue section. Mass cytometry imaging (imaging mass cytometry or multiplexed ion beam imaging) enables quantification of dozens of proteins simultaneously at subcellular resolution, placing ALS2 within its broader proteomic landscape across different brain regions and cell types. Spatial transcriptomics combined with ALS2 immunolabeling can correlate protein localization with regional gene expression profiles in disease models. Sequential immunolabeling approaches allow unlimited parameter imaging by iterative staining, imaging, and signal removal, enabling comprehensive characterization of ALS2's relationship to numerous cellular components. When applied to human post-mortem tissues, these techniques could reveal cell type-specific changes in ALS2 distribution across disease stages. For in vivo applications, developing near-infrared fluorescent antibody conjugates could enable longitudinal imaging of ALS2 in animal models using techniques like intravital microscopy to track dynamic changes during disease progression.